ROSE AMPADU: Open Payments
NPI 1366997561 · ELGIN, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,482 in 60 payments from 20 companies in 2025. Trend: 2023 $3,250 · 2024 $1,935 · 2025 $1,482
Food & beverage: $1,482
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $244 |
| Janssen Pharmaceuticals, Inc | 7 | $179 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $159 |
| Supernus Pharmaceuticals, Inc. | 5 | $138 |
| E.R. Squibb & Sons, L.L.C. | 4 | $95 |
| Alkermes, Inc. | 4 | $94 |
| ABBVIE INC. | 3 | $94 |
| Neurocrine BioSciences, Inc. | 2 | $64 |
| Vanda Pharmaceuticals Inc. | 2 | $58 |
| Braeburn Inc. | 2 | $58 |
Products named: REXULTI, CAPLYTA, Qelbree, SPRAVATO, COBENFY, VRAYLAR, INVEGA SUSTENNA, ABILIFY ASIMTUFII.
Industry payments across IL — which companies pay providers there.
